Cargando…

Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction

Mass spectrometry (MS) is the state-of-the-art methodology for capturing the breadth and depth of the immunopeptidome across human leukocyte antigen (HLA) allotypes and cell types. The majority of studies in the immunopeptidomics field are discovery driven. Hence, data-dependent tandem MS (MS/MS) ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Pak, HuiSong, Michaux, Justine, Huber, Florian, Chong, Chloe, Stevenson, Brian J., Müller, Markus, Coukos, George, Bassani-Sternberg, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724634/
https://www.ncbi.nlm.nih.gov/pubmed/33845167
http://dx.doi.org/10.1016/j.mcpro.2021.100080
_version_ 1784625947018788864
author Pak, HuiSong
Michaux, Justine
Huber, Florian
Chong, Chloe
Stevenson, Brian J.
Müller, Markus
Coukos, George
Bassani-Sternberg, Michal
author_facet Pak, HuiSong
Michaux, Justine
Huber, Florian
Chong, Chloe
Stevenson, Brian J.
Müller, Markus
Coukos, George
Bassani-Sternberg, Michal
author_sort Pak, HuiSong
collection PubMed
description Mass spectrometry (MS) is the state-of-the-art methodology for capturing the breadth and depth of the immunopeptidome across human leukocyte antigen (HLA) allotypes and cell types. The majority of studies in the immunopeptidomics field are discovery driven. Hence, data-dependent tandem MS (MS/MS) acquisition (DDA) is widely used, as it generates high-quality references of peptide fingerprints. However, DDA suffers from the stochastic selection of abundant ions that impairs sensitivity and reproducibility. In contrast, in data-independent acquisition (DIA), the systematic fragmentation and acquisition of all fragment ions within given isolation m/z windows yield a comprehensive map for a given sample. However, many DIA approaches commonly require generating comprehensive DDA-based spectrum libraries, which can become impractical for studying noncanonical and personalized neoantigens. Because the amount of HLA peptides eluted from biological samples such as small tissue biopsies is typically not sufficient for acquiring both meaningful DDA data necessary for generating comprehensive spectral libraries and DIA MS measurements, the implementation of DIA in the immunopeptidomics translational research domain has remained limited. We implemented a DIA immunopeptidomics workflow and assessed its sensitivity and accuracy by matching DIA data against libraries with growing complexity—from sample-specific libraries to libraries combining 2 to 40 different immunopeptidomics samples. Analyzing DIA immunopeptidomics data against a complex multi-HLA spectral library resulted in a two-fold increase in peptide identification compared with sample-specific library and in a three-fold increase compared with DDA measurements, yet with no detrimental effect on the specificity. Furthermore, we demonstrated the implementation of DIA for sensitive personalized neoantigen discovery through the analysis of DIA data with predicted MS/MS spectra of clinically relevant HLA ligands. We conclude that a comprehensive multi-HLA library for DIA approach in combination with MS/MS prediction is highly advantageous for clinical immunopeptidomics, especially when low amounts of biological samples are available.
format Online
Article
Text
id pubmed-8724634
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-87246342022-01-11 Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction Pak, HuiSong Michaux, Justine Huber, Florian Chong, Chloe Stevenson, Brian J. Müller, Markus Coukos, George Bassani-Sternberg, Michal Mol Cell Proteomics Technological Innovation and Resources Mass spectrometry (MS) is the state-of-the-art methodology for capturing the breadth and depth of the immunopeptidome across human leukocyte antigen (HLA) allotypes and cell types. The majority of studies in the immunopeptidomics field are discovery driven. Hence, data-dependent tandem MS (MS/MS) acquisition (DDA) is widely used, as it generates high-quality references of peptide fingerprints. However, DDA suffers from the stochastic selection of abundant ions that impairs sensitivity and reproducibility. In contrast, in data-independent acquisition (DIA), the systematic fragmentation and acquisition of all fragment ions within given isolation m/z windows yield a comprehensive map for a given sample. However, many DIA approaches commonly require generating comprehensive DDA-based spectrum libraries, which can become impractical for studying noncanonical and personalized neoantigens. Because the amount of HLA peptides eluted from biological samples such as small tissue biopsies is typically not sufficient for acquiring both meaningful DDA data necessary for generating comprehensive spectral libraries and DIA MS measurements, the implementation of DIA in the immunopeptidomics translational research domain has remained limited. We implemented a DIA immunopeptidomics workflow and assessed its sensitivity and accuracy by matching DIA data against libraries with growing complexity—from sample-specific libraries to libraries combining 2 to 40 different immunopeptidomics samples. Analyzing DIA immunopeptidomics data against a complex multi-HLA spectral library resulted in a two-fold increase in peptide identification compared with sample-specific library and in a three-fold increase compared with DDA measurements, yet with no detrimental effect on the specificity. Furthermore, we demonstrated the implementation of DIA for sensitive personalized neoantigen discovery through the analysis of DIA data with predicted MS/MS spectra of clinically relevant HLA ligands. We conclude that a comprehensive multi-HLA library for DIA approach in combination with MS/MS prediction is highly advantageous for clinical immunopeptidomics, especially when low amounts of biological samples are available. American Society for Biochemistry and Molecular Biology 2021-04-09 /pmc/articles/PMC8724634/ /pubmed/33845167 http://dx.doi.org/10.1016/j.mcpro.2021.100080 Text en © 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Technological Innovation and Resources
Pak, HuiSong
Michaux, Justine
Huber, Florian
Chong, Chloe
Stevenson, Brian J.
Müller, Markus
Coukos, George
Bassani-Sternberg, Michal
Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title_full Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title_fullStr Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title_full_unstemmed Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title_short Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction
title_sort sensitive immunopeptidomics by leveraging available large-scale multi-hla spectral libraries, data-independent acquisition, and ms/ms prediction
topic Technological Innovation and Resources
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724634/
https://www.ncbi.nlm.nih.gov/pubmed/33845167
http://dx.doi.org/10.1016/j.mcpro.2021.100080
work_keys_str_mv AT pakhuisong sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT michauxjustine sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT huberflorian sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT chongchloe sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT stevensonbrianj sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT mullermarkus sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT coukosgeorge sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction
AT bassanisternbergmichal sensitiveimmunopeptidomicsbyleveragingavailablelargescalemultihlaspectrallibrariesdataindependentacquisitionandmsmsprediction